1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Rosacea Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Erythematotelangiectatic Rosacea
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Papulopustular Rosacea
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Ocular Rosacea
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Phymatous Rosacea
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Antibiotics
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Alpha Agonists
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Retinoids
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Corticosteroids
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Immunosuppressants
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Antihypertensive Agents
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Topical
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Oral
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacy
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Online Pharmacy
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Retail Pharmacy
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by End User
10.1 Hospitals
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Homecare
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Specialty Clinics
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Bausch Health Companies Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Cellix Bio Private Limited
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.3 Colorescience Inc.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.4 Croda International Plc
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Galderma S.A.
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.6 LEO Pharma A/S
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 SWOT Analysis
16.3.7 Lupin Limited
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Maruho Co. Ltd.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 SWOT Analysis
16.3.9 PruGen Pharmaceuticals
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.10 Sol-Gel Technologies Ltd.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.11 Timber Pharmaceuticals LLC
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
